[1] Wong ALA, Hirpara JL, Pervaiz S, Eu JQ, Sethi G, Goh BC. Do STAT3 inhibitors have potential in the future for cancer therapy? Expert Opin Investig Drugs. 2017 Aug;26(8):883-887. doi: 10.1080/13543784.2017.1351941. Epub 2017 Jul 17.
[2] Yu H, Jove R. The STATs of cancer–new molecular targets come of age. Nat Rev Cancer. 2004 Feb;4(2):97-105.
[3] Lee HJ, Zhuang G, Cao Y, Du P, Kim HJ, Settleman J. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell. 2014 Aug 11;26(2):207-21. doi: 10.1016/j.ccr.2014.05.019. Epub 2014 Jul 24.
[4] Becker TM, Boyd SC, Mijatov B, Gowrishankar K, Snoyman S, Pupo GM, Scolyer RA, et al. Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor. Oncogene. 2014 Feb 27;33(9):1158-66. doi: 10.1038/onc.2013.45. Epub 2013 Mar 4.
[5] Alvarez JV, Greulich H, Sellers WR, Meyerson M, Frank DA. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res. 2006 Mar 15;66(6):3162-8.
Home Wong ALA, Hirpara JL
